Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration approved SIVEXTRO (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI).

21 Jun 2014

Yap1 oncogene drives recurrence and progression of pancreatic cancer

Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.

20 Jun 2014

Review on effects of treating cholera with antimicrobial drugs

Researchers from the Cochrane Infectious Diseases Group, co-ordinated through the editorial base in LSTM, conducted an independent review of the effects of treating cholera with antimicrobial drugs, published in The Cochrane Library today.

19 Jun 2014

Debiopharm launches Phase 1 study of anti-infective agent Debio 1450

Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).

19 Jun 2014

Fecal microbiota transplantation works by restoring healthy bacteria and functioning to recipient's gut

Fecal microbiota transplantation --- the process of delivering stool bacteria from a healthy donor to a patient suffering from intestinal infection with the bacterium Clostridium difficile --- works by restoring healthy bacteria and functioning to the recipient's gut, according to a study published this week in mBio-, the online open-access journal of the American Society for Microbiology.

17 Jun 2014

Delphi Genetics announces new license agreement for use of StabyExpress technology in food industry

Delphi Genetics SA has announced today a new license agreement for the use of the StabyExpress® technology in the food industry. The technology will be used for the production of enzymes for food processing.

17 Jun 2014

State highlights: New La. abortion restrictions; new Mass. hospital deal; Medicare and ambulances in N.J.

A selection of health policy stories from Louisiana, Massachusetts, New Jersey, Wisconsin, Georgia, Missouri, Maryland, New York, Kansas and Washington state.

16 Jun 2014

Specific enzyme helps protect good commensal bacteria from harmful effects of antibiotics

Researchers from Case Western Reserve University in Cleveland have discovered that populating the gastrointestinal (GI) tracts of mice with Bacteroides species producing a specific enzyme helps protect the good commensal bacteria from the harmful effects of antibiotics.

13 Jun 2014

Investigators isolate protein that is responsible for fungus' ability to cross blood-brain barrier

In a remarkable series of experiments on a fungus that causes cryptococcal meningitis, a deadly infection of the membranes that cover the spinal cord and brain, investigators at UC Davis have isolated a protein that appears to be responsible for the fungus' ability to cross from the bloodstream into the brain.

13 Jun 2014

Bacteria must be considered part of overall pathology of atherosclerosis

Scientists believe they have an explanation for the axiom that stress, emotional shock, or overexertion may trigger heart attacks in vulnerable people. Hormones released during these events appear to cause bacterial biofilms on arterial walls to disperse, allowing plaque deposits to rupture into the bloodstream, according to research published in published today in mBio-, the online open-access journal of the American Society for Microbiology.

11 Jun 2014

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, today announced that they have entered into an agreement to conduct metagenomic research on the effects of beta-lactam antibiotics on the gastrointestinal microflora (microbiome) of human patients.

10 Jun 2014

Chronic sleep loss can cause certain neurotoxic molecules to permeate into brain tissue

The longer the insomnia, junctions of cerebral blood vessels begin to degrade. In search of the answer to why do we sleep, research conducted at the Mexican Metropolitan Autonomous University (UAM) revealed that chronic sleep loss can cause certain neurotoxic molecules, which normally circulate in the blood, to be transported to the central nervous system and interfere with the function of neurons.

10 Jun 2014

Researchers solve structure of key protein that drives DNA copying in plasmids

Staph infections that become resistant to multiple antibiotics don't happen because the bacteria themselves adapt to the drugs, but because of a kind of genetic parasite they carry called a plasmid that helps its host survive the antibiotics.

10 Jun 2014

Aradigm’s common shares approved for listing on NASDAQ Capital Market

Aradigm Corporation is pleased to announce that its common shares have been approved for listing on the NASDAQ Capital Market.

9 Jun 2014

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that The Lancet Infectious Diseases published online the positive results from ESTABLISH-2, a pivotal Phase 3 clinical trial of the investigational antibiotic SIVEXTRO™ (tedizolid phosphate), which is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and soft tissue infections (cSSTI).

9 Jun 2014

TeleTracking’s hand hygiene technology redefines infection prevention standards at New Cross Hospital

New Cross Hospital, part of The Royal Wolverhampton NHS Trust, today announced a milestone of one million hand hygiene observations using TeleTracking Technologies, Inc.'s automated hand hygiene sensor as part of the 'Safe Hands' program.

9 Jun 2014

Scientists identify new way to reactivate latent HIV

A team of scientists at the Gladstone Institutes has identified a new way to make latent HIV reveal itself, which could help overcome one of the biggest obstacles to finding a cure for HIV infection.

6 Jun 2014

NEJM publishes results from SOLO I Phase 3 clinical trial of ORBACTIV for ABSSSI

The Medicines Company today announced the publication of the results from the SOLO I Phase 3 clinical trial of ORBACTIV (oritavancin), an investigational intravenous antibiotic treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), in the New England Journal of Medicine.

5 Jun 2014

New single-dose antibiotic is as effective as twice-daily infusion given for up to 10 days

In the battle against stubborn skin infections, including methicillin-resistant Staphylococcus aureus (MRSA), a new single-dose antibiotic is as effective as a twice-daily infusion given for up to 10 days, according to a large study led by Duke Medicine researchers.

5 Jun 2014

New antibiotic proves effective in treating serious bacterial skin and skin-structure infections

A study published in today's New England Journal of Medicine reports that the antibiotic dalbavancin is as effective as vancomycin, the current standard-of-care antibiotic used to treat serious bacterial skin and skin-structure infections.

5 Jun 2014

Antibiotic News and Research

Further Reading

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Yap1 oncogene drives recurrence and progression of pancreatic cancer

Review on effects of treating cholera with antimicrobial drugs

Debiopharm launches Phase 1 study of anti-infective agent Debio 1450

Fecal microbiota transplantation works by restoring healthy bacteria and functioning to recipient's gut

Delphi Genetics announces new license agreement for use of StabyExpress technology in food industry

State highlights: New La. abortion restrictions; new Mass. hospital deal; Medicare and ambulances in N.J.

Specific enzyme helps protect good commensal bacteria from harmful effects of antibiotics

Investigators isolate protein that is responsible for fungus' ability to cross blood-brain barrier

Bacteria must be considered part of overall pathology of atherosclerosis

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Chronic sleep loss can cause certain neurotoxic molecules to permeate into brain tissue

Researchers solve structure of key protein that drives DNA copying in plasmids

Aradigm’s common shares approved for listing on NASDAQ Capital Market

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

TeleTracking’s hand hygiene technology redefines infection prevention standards at New Cross Hospital

Scientists identify new way to reactivate latent HIV

NEJM publishes results from SOLO I Phase 3 clinical trial of ORBACTIV for ABSSSI

New single-dose antibiotic is as effective as twice-daily infusion given for up to 10 days

New antibiotic proves effective in treating serious bacterial skin and skin-structure infections

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News